Alira Health

Renee Willmon and MG Registry featured in new Rare Disease Article Series

Alira Health’s Senior Director of Evidence and Outcomes Renee Willmon was recently featured in the new Rare Community Profiles series on Patient Worthy®. In the article, “Alira Health and the MGFA Partner to Develop a Myasthenia Gravis Registry,” Renee shares how her professional journey has led her to her current involvement in patient registry development.

Renee Willmon is the Registry Lead on the Alira Health side of the partnership with MGFA, and works with both teams to ensure that MG patients’ experiences are well-represented in the registry and that other stakeholders can access and use the data to improve the development of new treatments, and access to care for MG.

I was really interested in the vision of empowering patients to take a more active role in shared decision-making, the health data they’re generating, and how they can use technology to democratize clinical research."
Renee Willmon Senior Director of Evidence and Outcomes, Alira Health

Patient Worthy® is an online publication that provides relevant information to rare disease patients, caregivers and advocates alike. Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.

Related news

Case Studies March 20, 2025
Pharma Company Defines Advocacy Strategy Through Data-Driven Patient Association Mapping
Alira Health mapped 253 CVRM patient advocacy groups across 11 countries, delivering a data-driven strategy to optimize partnerships, advocacy efforts, and differentiation.
Patient Advocacy Patient Engagement Pharma
Articles March 13, 2025
Beyond Patient Advisory Boards: Expanding Methods for Patient-Centered Insights in Healthcare
Explore innovative ways to gather patient insights for your product development beyond traditional advisor boards.
Patient Advocacy Patient Centricity Patient Engagement
Case Studies March 6, 2025
Rare Disease Pharma Maps Rare Cholestatic Liver Disease Journey for Targeted Patient Engagement
A global pharmaceutical company specializing in rare diseases, oncology, and neuroscience sought to analyze the patient journey for progressive familial intrahepatic cholestasis (PFIC).
Patient Centricity Pharma Rare Disease
Articles February 17, 2025
Rethinking Rare Disease Development: An Integrated, Patient Access-Driven Approach
Explore how biotech companies can succeed in rare disease by integrating development, commercialization, and patient access.
Patient Centricity Pharma Rare Disease
Articles February 11, 2025
From Diagnosis to Long-Term Care: Navigating the Rare Disease Journey
For Rare Disease Day, we spoke with patient engagement expert Luca Trentin on challenges faced by rare disease patients and how pharma can better understand their needs.
Patient Centricity Pharma Rare Disease
Articles October 28, 2024
How to Co-create Successful Market Access Strategies With Patients for Rare Disease Treatments
Engaging directly with patients can help pharma and biotech companies gather crucial data that strengthens the evidence supporting their market access efforts.
Market Access Rare Disease
Articles October 16, 2024
Pharma’s Essential Role in Strengthening Patient Involvement in Health Technology Assessments
Pharma companies play a key role in successfully involving patients in the HTA process, and to learn more, we spoke with expert Luca Trentin.
Healthcare Technology Orphan Drug Rare Disease
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.